Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
Clinical trial NCT03833427 · TERMINATED
Trial details
- NCT number
- NCT03833427
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-18
- Primary completion
- 2022-06-28
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.